Topical resiquimod dosing regimens in patients with multiple actinic keratoses: a multicentre, partly placebo-controlled, double-blind clinical trial

The British Journal of Dermatology
Eggert StockflethLars E French

Abstract

Topical immune response modifiers are established for actinic keratosis (AK) treatment and efforts are underway to make further improvements to their efficacy and safety. To investigate the optimal dosing regimens of the Toll-like receptor 7/8 agonist resiquimod in terms of efficacy, safety and tolerability. In a multicentre, partly placebo-controlled, double-blind clinical trial, we randomized 217 patients with AK lesions to 0·03% resiquimod gel once-daily application three times per week for 4 weeks or seven times within 2 weeks or five times for 1 week (arms 1/2/3) followed by a treatment-free interval of 8 weeks and one repetition of the cycle. In two additional arms (arms 4/5), patients applied either resiquimod gel 0·01% or 0·03% three times per week up to a biological end point defined by skin erosion or for a maximum duration of 8 weeks. Clearance was assessed clinically and histologically. Complete clinical clearance ranged from 56% to 85% with the highest rate observed in arm 2. Resiquimod 0·03% gel was more effective than 0·01% gel. Clearance rates in arms 1/2/3 were comparable and higher than with placebo and were reached with 24, 14 and 10 gel applications, respectively. Overall, 128 patients (59%) experienced trea...Continue Reading

References

Oct 8, 1998·International Journal of Dermatology·M A MittelbronnF P Flowers
Aug 25, 1999·Journal of the American Academy of Dermatology·S T GuenthnerH R Gray
Dec 22, 1999·Journal of the American Academy of Dermatology·S J Salasche
Apr 16, 2002·Journal of Cutaneous Medicine and Surgery·D CzarneckiG Culjak
Jan 21, 2003·Archives of Dermatology·Wendy Fu, Clay J Cockerell
Jul 9, 2004·Dermatology : International Journal for Clinical and Investigative Dermatology·Matthias AugustinUwe Gieler
May 15, 2008·The British Journal of Dermatology·R-M SzeimiesT-C Meng
Jul 31, 2010·Expert Opinion on Emerging Drugs·Martina UlrichEggert Stockfleth
Mar 16, 2012·The New England Journal of Medicine·Mark LebwohlBrian Berman
Dec 5, 2012·Expert Opinion on Investigational Drugs·Thomas MeyerEggert Stockfleth
Mar 21, 2013·The Journal of Investigative Dermatology·Sophie C FlohilTamar Nijsten
May 8, 2013·The British Journal of Dermatology·R N WernerA Nast
Mar 15, 2014·Dermatology and Therapy·Annabel DoddsStephen Shumack
Aug 2, 2014·Oncoimmunology·Fernando ArandaLorenzo Galluzzi
Jun 13, 2015·Acta Dermato-venereologica·Eggert StockflethIvette Alarcon
Nov 22, 2016·The Journal of Clinical Investigation·Trevor J CunninghamShadmehr Demehri
Jan 18, 2017·The British Journal of Dermatology·D de BerkerB R Hughes

❮ Previous
Next ❯

Citations

Feb 5, 2019·The British Journal of Dermatology·R Rajaratnam
Jan 9, 2021·Expert Opinion on Emerging Drugs·Florian Herms, Nicole Basset-Seguin
Nov 10, 2021·Expert Opinion on Emerging Drugs·Morgan A FarrDaniel J Lewis

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.